TY - JOUR
T1 - Inclisiran
T2 - Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia
AU - Hughes-Hubley, Frances
AU - Iskander, Mina
AU - Cheng-Lai, Angela
AU - Frishman, William H.
AU - Nawarskas, James
N1 - Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Elevated plasma lipid levels, especially low-density lipoprotein, are correlated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of ischemic heart disease and stroke. Statins are first-line agents for reducing low-density lipoprotein cholesterol (LDL-C) and the risk of major cardiovascular events, but patients with a genetic susceptibility or established ASCVD oftentimes remain subtherapeutic on statin therapy alone. Biotechnological advancements in medication therapy have led to the development of inclisiran, a recently approved twice-yearly injectable agent to help patients with heterozygous familial hypercholesterolemia and clinical ASCVD on a maximally tolerated statin to reach LDL-C targets. Inclisiran has demonstrated robust LDL-C reduction in clinical trials in combination with a favorable safety profile; however, the effect on cardiovascular clinical outcomes still remains under evaluation.
AB - Elevated plasma lipid levels, especially low-density lipoprotein, are correlated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of ischemic heart disease and stroke. Statins are first-line agents for reducing low-density lipoprotein cholesterol (LDL-C) and the risk of major cardiovascular events, but patients with a genetic susceptibility or established ASCVD oftentimes remain subtherapeutic on statin therapy alone. Biotechnological advancements in medication therapy have led to the development of inclisiran, a recently approved twice-yearly injectable agent to help patients with heterozygous familial hypercholesterolemia and clinical ASCVD on a maximally tolerated statin to reach LDL-C targets. Inclisiran has demonstrated robust LDL-C reduction in clinical trials in combination with a favorable safety profile; however, the effect on cardiovascular clinical outcomes still remains under evaluation.
KW - cholesterol
KW - inclisiran
KW - lipid-lowering therapy
KW - small interfering ribonucleic acid
KW - statin
UR - http://www.scopus.com/inward/record.url?scp=85131338687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131338687&partnerID=8YFLogxK
U2 - 10.1097/CRD.0000000000000452
DO - 10.1097/CRD.0000000000000452
M3 - Review article
C2 - 35666780
AN - SCOPUS:85131338687
SN - 1061-5377
VL - 30
SP - 214
EP - 219
JO - Cardiology in review
JF - Cardiology in review
IS - 4
ER -